β1- and β2-adrenergic Receptor Haplotypes Regulate Therapeutic Responses to Placebo and the Biased Ligand β-blocker Bucindolol
Ian A. Carroll, Dobromir B. Slavov, Eric R. Jonas, Wayne A. Minobe, Lori A. Walker, Amrut V. Ambardekar, Timothy A. McKinsey, Ammon D. Knaupp, Donghwa Kim, Stephen B. Liggett, Michael R. Bristow
This paper shows that β1- and β2-adrenergic receptor haplotypes influence responses to bucindolol and placebo in heart failure patients, with internalizing haplotypes providing protection and bucindolol being effective in internalization-resistant ones.
medRxiv · Aug 22, 2025 · PreprintGenetic & Genomic Medicine